Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate

Patent No. EP2508188 (titled "Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate") was filed by Astrazeneca on Mar 21, 2008. The application was issued on May 10, 2023.

Patent Summary

Immediate release pharmaceutical formulations, including capsules and tablets, containing the SGLT2 inhibitor dapagliflozin for treating and delaying progression of diseases associated with SGLT2 activity, such as diabetes. The formulations include a stock granulation containing dapagliflozin as the active ingredient along with excipients like binders, fillers, disintegrants, lubricants, and anti-adherents. The granules can be loaded into capsules or compressed into tablets for oral administration. The formulations aim to improve bioavailability and patient compliance of dapagliflozin, a drug that reduces glucose reabsorption in the kidneys.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2508188

ASTRAZENECA
Application Number
EP12153939A
Filing Date
Mar 21, 2008
Status
Granted And Under Opposition
Apr 7, 2023
Publication Date
May 10, 2023